XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic earnings per share (“EPS”) represents income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common shares (such as unexercised stock options and unvested restricted stock) were exercised or converted into additional common shares that would then share in the earnings of the entity. Diluted EPS is computed by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding for the period, plus the effect of potential dilutive common share equivalents.
Shares held by the Employee Stock Ownership Plan (“ESOP”) that have not been allocated to employees in accordance with the terms of the ESOP, referred to as “unallocated ESOP shares,” are not deemed outstanding for earnings per share calculations.
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
(Income In thousands)
Net (loss) income applicable to common shares$(1,825)$40 $(3,034)$593 
Shares
Average number of common shares outstanding26,314,743 28,522,500 26,184,419 28,522,500 
Less: Average unallocated ESOP shares2,065,029 2,156,176 2,053,402 2,167,521 
Average number of common shares outstanding used to calculate basic earnings per common share24,249,714 26,366,324 24,131,017 26,354,979 
Common stock equivalents— — — — 
Average number of common shares outstanding used to calculate diluted earnings per common share24,249,714 26,366,324 24,131,017 26,354,979 
Earnings per common share
Basic$(0.08)$— $(0.13)$0.02 
Diluted$(0.08)$— $(0.13)$0.02 
Excluded from the earnings per share calculation are anti-dilutive equity awards for the three and six months ended June 30, 2023, totaling 1,490,010 and 1,177,136, respectively. There were no securities or other contracts that had a dilutive effect for the three and six months ended June 30, 2022. Due to the Company’s net loss three and six months ended June 30, 2023, the assumed vesting of outstanding restricted stock units had an antidilutive effect on diluted earnings per share.